Verduyn-van Weegen Felice Isabel 4
4 · Evommune, Inc. · Filed Nov 12, 2025
Insider Transaction Report
Form 4
Evommune, Inc.EVMN
Verduyn-van Weegen Felice Isabel
Director10% Owner
Transactions
- Conversion
Common Stock
2025-11-07+3,367,133→ 3,367,133 total(indirect: By LSP 7 Cooperatief U.A.) - Conversion
Series C Preferred Stock
2025-11-07−6,585,011→ 0 total(indirect: By LSP 7 Cooperatief U.A.)→ Common Stock (773,069 underlying) - Purchase
Common Stock
2025-11-07$16.00/sh+1,562,500$25,000,000→ 4,929,633 total(indirect: By LSP 7 Cooperatief U.A.) - Conversion
Series A Preferred Stock
2025-11-07−15,493,466→ 0 total(indirect: By LSP 7 Cooperatief U.A.)→ Common Stock (1,947,477 underlying) - Conversion
Series B Preferred Stock
2025-11-07−5,090,000→ 0 total(indirect: By LSP 7 Cooperatief U.A.)→ Common Stock (646,587 underlying)
Footnotes (4)
- [F1]Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date.
- [F2]Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.
- [F3]Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.
- [F4]These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein.